Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
1.440
+0.120 (9.09%)
At close: Nov 4, 2024, 4:00 PM
1.461
+0.020 (1.42%)
After-hours: Nov 4, 2024, 5:09 PM EST
Xilio Therapeutics Employees
Xilio Therapeutics had 73 employees as of December 31, 2023. The number of employees decreased by 16 or -17.98% compared to the previous year.
Employees
73
Change (1Y)
-16
Growth (1Y)
-17.98%
Revenue / Employee
$32,288
Profits / Employee
-$897,685
Market Cap
63.29M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 73 | -16 | -17.98% |
Dec 31, 2022 | 89 | 15 | 20.27% |
Dec 31, 2021 | 74 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Prenetics Global | 324 |
Enzo Biochem | 190 |
Barinthus Biotherapeutics | 130 |
Mural Oncology | 117 |
VolitionRx | 110 |
Theratechnologies | 103 |
Aligos Therapeutics | 66 |
enVVeno Medical | 31 |
XLO News
- 5 days ago - Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewsWire
- 4 weeks ago - Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewsWire
- 4 weeks ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results - GlobeNewsWire
- 5 months ago - Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D. - GlobeNewsWire
- 6 months ago - Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results - GlobeNewsWire
- 7 months ago - Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire